DREAMM-9: Phase I Study of Belantamab Mafodotin with Standard of Care in non-transplant-eligible Patients with newly diagnosed multiple Myeloma

被引：0

作者：

Raab, M. S. ^{[1
]}

Usmani, S. Z. ^{[2
]}

Mielnik, M. ^{[3
]}

Koh, Y. ^{[4
]}

Alonso Alonso, A. ^{[5
]}

Leleu, X. ^{[6
]}

Quach, H. ^{[7
]}

Min, C-K. ^{[8
]}

Janowski, W. ^{[9
]}

Abdallah, A. -O. ^{[10
]}

Garg, M. ^{[11
]}

Sandhu, I. ^{[12
]}

San Miguel, Ocio E. M. ^{[13
]}

Oriol, A. ^{[14
,15
]}

Rodriguez-Otero, P. ^{[16
]}

Ramasamy, K. ^{[17
]}

Weisel, K. ^{[18
]}

Besemer, B. ^{[19
]}

Cavo, M. ^{[20
]}

Zhou, X. L. ^{[21
]}

Kaisermann, M. C. ^{[22
]}

Bego Marques, C. M. ^{[23
]}

Williams, D. ^{[22
]}

Carreno, F. ^{[22
]}

Kremer, B. E. ^{[22
]}

Gupta, I. V. ^{[22
]}

Hus, M. ^{[3
]}

机构：

[1] Univ Hosp Heidelberg, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Med Univ Lublin, Dept Hematooncol & Bone Marrow Transplantat, Lublin, Poland

[4] Seoul Natl Univ Hosp, Seoul, South Korea

[5] Hosp Quiron Madrid, Madrid, Spain

[6] CHU Poitiers, Poitiers, France

[7] St Vincent Hosp Melbourne, Melbourne, Vic, Australia

[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[9] Calvary Mater Newcastle, Newcastle, NSW, Australia

[10] Univ Kansas, Kansas City, KS USA

[11] Leicester Royal Infirm, Leicester, Leics, England

[12] Univ Alberta, Edmonton, AB, Canada

[13] Univ Cantabria, Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain

[14] Hosp Univ Germans Trias & Pujol HUGTP, Inst Catala Oncol, Badalona, Spain

[15] Hosp Univ Germans Trias & Pujol HUGTP, Inst Josep Carreras, Badalona, Spain

[16] Clin Univ Navarra, Dept Hematol, Pamplona, Spain

[17] Churchill Hosp, Oxford, England

[18] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[19] Univ Tubingen, Tubingen, Germany

[20] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[21] GlaxoSmithKline, Waltham, MA USA

[22] GlaxoSmithKline, Upper Providence, PA USA

[23] GlaxoSmithKline, Barcelona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P433

引用

页码：145 / 146

页数：2

共 50 条

[41] Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible
Soutar, R.
Steel, M.
Donaldson, A.
Walbaum, C.
ANNALS OF HEMATOLOGY, 2020, 99 (04) : 905 - 906
[42] A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Terpos, Evangelos
Kastritis, Efstathios
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Kanellias, Nikolaos
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Dimopoulos, Meletios A.
BLOOD, 2022, 140 : 12616 - 12617
[43] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Kanagavel, Dheepak
Fitzmaurice, Thomas F.
Wu, Junlong
Martinez Lopez, Joaquin
BLOOD, 2018, 132
[44] Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients
Kostopoulos, Ioannis V.
Kakalis, Antonis
Birmpilis, Anastasios
Angelis, Nikolaos
Orologas-Stavrou, Nikolaos
Rousakis, Pantelis
Panteli, Chrysanthi
Gavriatopoulou, Maria
Kastritis, Efstathios
Dimopoulos, Meletios-Athanasios
Tsitsilonis, Ourania
Terpos, Evangelos
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : E65 - E67
[45] Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lonial, Sagar
Lee, Hans C.
Badros, Ashraf
Trudel, Suzanne
Nooka, Ajay K.
Chari, Ajai
Abdallah, Al-Ola
Callander, Natalie
Lendvai, Nikoletta
Sborov, Douglas
Suvannasankha, Attaya
Weisel, Katja
Karlin, Lionel
Libby, Edward
Arnulf, Bertrand
Facon, Thierry
Hulin, Cyrille
Kortum, K. Martin
Rodriguez-Otero, Paula
Usmani, Saad Z.
Hari, Parameswaran
Baz, Rachid
Hang Quach
Moreau, Philippe
Voorhees, Peter M.
Gupta, Ira
Hoos, Axel
Zhi, Eric
Baron, January
Piontek, Trisha
Lewis, Eric
Jewell, Roxanne C.
Dettman, Elisha J.
Popat, Rakesh
Esposti, Simona Degli
Opalinska, Joanna
Richardson, Paul
Cohen, Adam D.
LANCET ONCOLOGY, 2020, 21 (02): : 207 - 221
[46] Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
Cairns, David
Pawlyn, Charlotte
Royle, Kara-Louise
Best, Phillip
Bird, Jenny
Bowcock, Stella
Boyd, Kevin
Dawkins, Bryony
Drayson, Mark T.
Henderson, Rowena
Jenner, Matthew
Jones, John R.
Kaiser, Martin F.
Kishore, Bhuvan
Meads, David
Mottram, Rebecca
Rabin, Neil K.
Owen, Roger G.
Jackson, Graham
Cook, Gordon
BLOOD, 2019, 134
[47] Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Farooq, Asim, V
Degli Esposti, Simona
Popat, Rakesh
Thulasi, Praneetha
Lonial, Sagar
Nooka, Ajay K.
Jakubowiak, Andrzej
Sborov, Douglas
Zaugg, Brian E.
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Opalinska, Joanna
Baron, January
Piontek, Trisha
Byrne, Julie
Gupta, Ira
Colby, Kathryn
OPHTHALMOLOGY AND THERAPY, 2020, 9 (04) : 889 - 911
[48] Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Asim V. Farooq
Simona Degli Esposti
Rakesh Popat
Praneetha Thulasi
Sagar Lonial
Ajay K. Nooka
Andrzej Jakubowiak
Douglas Sborov
Brian E. Zaugg
Ashraf Z. Badros
Bennie H. Jeng
Natalie S. Callander
Joanna Opalinska
January Baron
Trisha Piontek
Julie Byrne
Ira Gupta
Kathryn Colby
Ophthalmology and Therapy, 2020, 9 : 913 - 915
[49] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Rifkin, Robert M.
Boyd, Kevin
Grosicki, Sebastian
Kim, Kihyun
Di Raimondo, Francesco
Dimopoulos, Meletios A.
Weisel, Katja
Arnulf, Bertrand
Hajek, Roman
Hungria, Vania T. M.
Spencer, Andrew
Davis, Randy
Riccio, Antonio
Kim, Chanbin
Wilkes, Jodie
Rutledge, Ruth
Talekar, Mala
Kremer, Brandon E.
Gupta, Ira
Mateos, Maria-Victoria
BLOOD, 2020, 136
[50] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Trudel, Suzanne
Davis, Randy
Lewis, Nicole M.
Bakshi, Kalpana K.
Chopra, Bikramjit
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Eliason, Laurie
Kremer, Brandon E.
Stowell, Delia
Gupta, Ira
Wu, Frank S.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177

← 1 2 3 4 5 →